Revive Therapeutics Proposes an Innovative Debt Settlement
Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a leading life sciences company, is excited to announce its strategic decision to settle outstanding debts amounting to $150,000. This move involves the issuance of up to 6,000,000 common shares at an estimated price of $0.025 per share, a price calculated based on the 20-day volume-weighted average price (VWAP) of shares traded on the Canadian Securities Exchange (CSE).
Rationale Behind the Share Issuance
The company prioritizes preserving its cash reserves for ongoing operations by opting for this share issuance rather than immediate cash payments. This decision allows Revive to allocate more funds toward its research and development initiatives, a key area for the company.
Details of the Debt Settlement
The issuance of shares as a form of settling debts is subject to customary conditions and regulations. Revive Therapeutics plans to complete this transaction promptly, ensuring that the settlement process is efficient and compliant. It’s important to note that the new shares will carry a hold period of four months plus one day from their issuance date.
The Company's Focus on Life Sciences
Revive Therapeutics is dedicated to the research and development of innovative therapeutics aimed at addressing infectious diseases and medical countermeasures. With a robust pipeline, Revive vigorously pursues regulatory incentives from the FDA, including Emergency Use Authorizations and Breakthrough Therapy designations. The company’s current research focuses on using Bucillamine as a potential treatment for various health issues, including nerve agent exposure and conditions like long COVID.
Advancements in Therapeutic Development
Besides Bucillamine, Revive is making strides in exploring therapies involving Psilocybin and molecular hydrogen. These ongoing programs reflect the company’s commitment to advancing healthcare solutions that meet critical medical needs. It’s a thrilling time for Revive as they continue to push the boundaries of conventional therapeutics to offer hope for many patients.
Outreach and Communication
For those interested in Revive Therapeutics and its initiatives, detailed information is available on their website. Michael Frank, the Chief Executive Officer, emphasizes the importance of open communication and encourages inquiries from stakeholders eager to learn more about the company's capabilities and advancements in the life sciences sector.
For additional information about Revive Therapeutics, Michael Frank can be contacted directly. The company's commitment to transparency and engagement is evident as they continue to share developments and respond to stakeholder concerns.
Frequently Asked Questions
What is the purpose of the share issuance by Revive Therapeutics?
The share issuance aims to settle $150,000 in debts while preserving cash for ongoing operations and enhancing research and development efforts.
How many shares will Revive Therapeutics issue for the debt settlement?
Revive plans to issue up to 6,000,000 common shares at a proposed issue price of $0.025 per share.
What is the duration of the hold period for the newly issued shares?
The shares issued will have a hold period of four months plus one day from the date of issuance.
What areas of research is Revive Therapeutics focused on?
Revive Therapeutics focuses on therapeutics for infectious diseases, rare disorders, and medical countermeasures.
Who can be contacted for more information regarding Revive Therapeutics?
Interested parties can reach out to Michael Frank, the Chief Executive Officer, for inquiries about Revive’s operations and initiatives.
